HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis.
暂无分享，去创建一个
B. Blumenstein | G. Selvaggi | U. Wiedermann | I. Nikolic | Z. Andrić | R. Nagarkar | N. Ede | L. Chong | A. Good | T. Chawla | Z. Petrović | M. Maglakelidze | I. Bulat | D. Ryspayeva | S. Yavrom | D. Ryspayeva | B. Nixon | S. Yavrom